



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

June 26, 2019

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2019.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajet Nair
Company Secretary

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2019

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company:
Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands
Wyeth LLC, USA
Wyeth Holdings Corporation, USA
John Wyeth & Brother Limited, UK
Warner - Lambert Company, LLC, USA
Parke - Davis & Company, LLC, USA
Pharmacia Corporation, USA
[Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India
Pfizer Innovative Supply Point Intl BVBA, Belgium
Pfizer Service Company BVBA, Belgium
Pfizer Worldwide Services, Ireland

D. Key managerial personnel

Mr. S. Sridhar - Managing Director
Mr. Milind Patil - Chief Financial Officer (w.e.f 16 August 2018)
Wholetime Director (w.e.f 14 November 2018)
Mr. Vivek Dhariwal - Wholetime Director
Dr. Anurita Majumdar - Wholetime Director (upto 8 March 2019)
Mr. R A Shah - Independent Director
Mr. Pradip Shah - Independent Director
Mr. Uday Khanna - Independent Director
Mr. Sunil Lalbhai - Independent Director
Ms.Meena Ganesh - Independent Director (w.e.f 8 March 2019)
Mr. Ravi Prakash Bhagavathula - Chief Financial Officer (upto 31 March 2018)
Wholetime Director (upto 28 February 2018)



Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2019

Currency: ₹ in crore

Related party transactions (Continued)

II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

No. Nature of transactions	31 March 2019				31 March 2018			
	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
1 Service income	0.37	-	50.56	50.93	1.27	-	54.02	55.29
2 Recovery of expenses	-	-	0.36	0.36	-	-	1.34	1.34
3 Purchase of stock-in-trade	-	-	396.42	396.42	-	-	273.63	273.63
4 Purchase of raw / bulk materials	-	-	49.98	49.98	-	-	59.83	59.83
5 Reimbursement of expenses	0.27	-	-	0.27	0.88	-	3.33	4.21
6 Dividend in respect of the year ended 31 March 2018 / 2017	-	58.49	-	58.49	-	58.49	-	58.49
7 Service charges	-	-	-	-	-	-	2.97	2.97
No. Nature of transactions	31 March 2019				31 March 2018			
No. Nature of transactions	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
8 Outstanding as at the year end – Due from	0.33	0.06	19.21	19.60	0.20	-	14.83	15.03
9 Outstanding as at the year end – Due to	10.52	7.84	254.97	273.33	9.76	7.76	290.15	307.67

Key managerial personnel

No. Nature of transactions	Year ended 31 March 2019	Year ended 31 March 2018
1 Remuneration to key management personnel *	10.39	10.06

* Excludes amounts payable to key management personnel towards gratuity, compensated absences and provident fund.

Details of material transactions during the year:

	Year ended 31 March 2019	Year ended 31 March 2018
a) Service income		
Pfizer Products India Private Limited	23.22	19.79
Pfizer Worldwide Services	27.34	34.23
b) Service charge		
Pfizer Products India Private Limited	-	2.97
c) Recovery of expenses		
Pfizer Products India Private Limited	0.34	1.31
d) Purchase of stock in trade		
Pfizer Innovative Supply Point Intl BVBA, Belgium	258.18	242.60
Pfizer Service Company BVBA, Belgium	131.93	27.49
e) Purchase of raw/ bulk materials		
Pfizer Service Company BVBA, Belgium	46.87	55.49
f) Reimbursement of expenses		
Pfizer Investment Co., Ltd	-	3.20
Pfizer Inc., USA	0.27	0.88
g) Dividend paid		
Pfizer East India B.V.	36.37	36.37
Wyeth LLC, USA	11.24	11.24
h) Remuneration to key management personnel		
S. Sridhar	3.55	3.43
Milind Patil	1.59	-
Vivek Dhariwal	2.53	1.92
Dr. Anurita Majumdar	1.96	1.74
Ravi Prakash Bhagavathula	-	2.30



Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2019

Currency: ₹ in crore

Related party transactions (Continued)

	As on 31 March 2019	As on 31 March 2018
i) Outstanding as at the year end due from		
Pfizer Worldwide Services	5.47	9.49
Pfizer Products India Private Limited, India	13.74	5.34
j) Outstanding as at the year end due to		
Pfizer Innovative Supply Point Intl BVBA, Belgium	62.49	145.27
Pfizer Service Company BVBA, Belgium	83.97	32.65
Pfizer Export Company, Ireland	84.70	57.41

